1. JAK/STAT Signaling
    Protein Tyrosine Kinase/RTK
  2. EGFR

Anlotinib 

Cat. No.: HY-19716 Purity: 99.65%
Data Sheet SDS Handling Instructions

Anlotinib is a EGFR inhibitor extracted from patent 2015185012 A1, compound 1,which can be used to treat non-small cell lung cancer.

For research use only. We do not sell to patients.
Anlotinib Chemical Structure

Anlotinib Chemical Structure

CAS No. : 1058156-90-3

Size Price Stock Quantity
10 mM * 1 mL in DMSO $385 In-stock
5 mg $350 In-stock
10 mg $500 In-stock
50 mg $1500 In-stock
100 mg $2100 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Featured Recommendations

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Anlotinib is a EGFR inhibitor extracted from patent 2015185012 A1, compound 1,which can be used to treat non-small cell lung cancer.

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT02809534 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Hepatocellular Carcinoma September 2016 Phase 2
NCT02072044 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Renal Cell Carcinoma(RCC) December 2013 Phase 2
NCT02072031 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Anlotinib|RCC December 2013 Phase 2
NCT02825563 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Advanced Cancer June 2016 Phase 1
NCT02649361 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Esophageal Squamous Cell Carcinoma January 2016 Phase 2
NCT02586350 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Medullary Thyroid Carcinoma July 2015 Phase 2|Phase 3
NCT02332499 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Metastatic Colorectal Cancer December 2014 Phase 2|Phase 3
NCT02752516 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Cancer April 27, 2016 Phase 1
NCT01924195 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Non-small Cell Lung Cancer August 2013 Phase 2
NCT02586337 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Differentiated Thyroid Cancer July 2015 Phase 2|Phase 3
NCT02622932 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Advanced Solid Tumors December 2, 2015 Phase 1
NCT03059797 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Small Cell Lung Cancer March 2017 Phase 2
NCT02449343 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Soft Tissue Sarcoma May 12, 2015 Phase 2|Phase 3
NCT02461407 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Gastric Cancer June 2015 Phase 2|Phase 3
NCT02388919 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Non-small Cell Lung Cancer February 26, 2015 Phase 2|Phase 3
NCT01878448 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Cancer April 2013 Phase 2
NCT01874873 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Tumor April 2013 Phase 2
NCT01833923 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd|Nanjing Medical University Advanced Cancer May 2011 Phase 1
NCT02029209 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd|Tianjin Medical University Cancer Institute and Hospital Non-small Cell Lung Cancer December 2013 Phase 2|Phase 3
NCT02809534 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Hepatocellular Carcinoma September 2016 Phase 2
NCT02072044 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Renal Cell Carcinoma(RCC) December 2013 Phase 2
NCT02072031 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Anlotinib|RCC December 2013 Phase 2
NCT02825563 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Advanced Cancer June 2016 Phase 1
NCT02649361 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Esophageal Squamous Cell Carcinoma January 2016 Phase 2
NCT02586350 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Medullary Thyroid Carcinoma July 2015 Phase 2|Phase 3
NCT02332499 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Metastatic Colorectal Cancer December 2014 Phase 2|Phase 3
NCT02752516 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Cancer April 27, 2016 Phase 1
NCT01924195 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Non-small Cell Lung Cancer August 2013 Phase 2
NCT02586337 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Differentiated Thyroid Cancer July 2015 Phase 2|Phase 3
NCT02622932 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Advanced Solid Tumors December 2, 2015 Phase 1
NCT03059797 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Small Cell Lung Cancer March 2017 Phase 2
NCT02449343 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Soft Tissue Sarcoma May 12, 2015 Phase 2|Phase 3
NCT02461407 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Gastric Cancer June 2015 Phase 2|Phase 3
NCT02388919 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Non-small Cell Lung Cancer February 26, 2015 Phase 2|Phase 3
NCT01878448 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Cancer April 2013 Phase 2
NCT01874873 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Tumor April 2013 Phase 2
NCT01833923 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd|Nanjing Medical University Advanced Cancer May 2011 Phase 1
NCT02029209 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd|Tianjin Medical University Cancer Institute and Hospital Non-small Cell Lung Cancer December 2013 Phase 2|Phase 3
View MoreCollapse
References
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 2.4543 mL 12.2717 mL 24.5435 mL
5 mM 0.4909 mL 2.4543 mL 4.9087 mL
10 mM 0.2454 mL 1.2272 mL 2.4543 mL
References
Molecular Weight

407.44

Formula

C₂₃H₂₂FN₃O₃

CAS No.

1058156-90-3

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥ 44 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Anlotinib
Cat. No.:
HY-19716
Quantity: